Answers are grounded in this paper and cite their sources.
Seventy-one patients with disseminated malignant melanoma were treated with combination chemotherapy consisting of dimethyl triazeno imidazole carboxamide (DTIC) and dactinomycin. An objective response rate of 20% was observed in 69 evaluable patients. The addition of dactinomycin with DTIC did not provide enhanced therapeutic benefit over that of DTIC as a single agent when compared to previous studies. There was increased toxicity. Problems of hemorrhage in metastatic cerebral lesions were encountered.
No takes yet. Share an insight, caveat, or question.
Gerner et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: